- Home
- ACAD vs RNA Comparison
ACAD vs RNA Comparison
Compare ACAD & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- RNA
- Stock Information
- Founded
- ACAD 1993
- RNA 2012
- Country
- ACAD United States
- RNA United States
- Employees
- ACAD N/A
- RNA N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- RNA Biotechnology: Pharmaceutical Preparations
- Sector
- ACAD Health Care
- RNA Health Care
- Exchange
- ACAD Nasdaq
- RNA Nasdaq
- Market Cap
- ACAD 3.5B
- RNA 4.0B
- IPO Year
- ACAD 2004
- RNA 2020
- Fundamental
- Price
- ACAD $23.53
- RNA $35.92
- Analyst Decision
- ACAD Buy
- RNA Strong Buy
- Analyst Count
- ACAD 18
- RNA 14
- Target Price
- ACAD $27.94
- RNA $67.71
- AVG Volume (30 Days)
- ACAD 1.7M
- RNA 2.9M
- Earning Date
- ACAD 08-06-2025
- RNA 08-12-2025
- Dividend Yield
- ACAD N/A
- RNA N/A
- EPS Growth
- ACAD N/A
- RNA N/A
- EPS
- ACAD 1.37
- RNA N/A
- Revenue
- ACAD $996,283,000.00
- RNA $8,927,000.00
- Revenue This Year
- ACAD $13.28
- RNA N/A
- Revenue Next Year
- ACAD $10.88
- RNA $196.18
- P/E Ratio
- ACAD $17.19
- RNA N/A
- Revenue Growth
- ACAD 22.42
- RNA N/A
- 52 Week Low
- ACAD $13.40
- RNA $21.51
- 52 Week High
- ACAD $25.23
- RNA $56.00
- Technical
- Relative Strength Index (RSI)
- ACAD 61.47
- RNA 60.60
- Support Level
- ACAD $22.40
- RNA $34.25
- Resistance Level
- ACAD $24.06
- RNA $39.00
- Average True Range (ATR)
- ACAD 0.72
- RNA 1.98
- MACD
- ACAD 0.09
- RNA 0.30
- Stochastic Oscillator
- ACAD 76.96
- RNA 58.27
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.